Connect to other sites within the UBM Medica Network
Results From the Multiple Myeloma Trials
We discuss some of the anticipated multiple myeloma trials with Sagar Lonial, MD, ahead of the 2015 American Society of Clinical Oncology Annual Meeting.
ASCT Offers Survival Advantage in Elderly Multiple Myeloma Patients
Autologous stem cell transplant led to significantly longer overall survival than non-transplant strategies in a cohort of elderly patients with multiple myeloma.
Adding Elotuzumab Improved PFS in Relapsed Multiple Myeloma
The addition of elotuzumab to lenalidomide and dexamethasone improved progression-free survival and overall response rate in relapsed multiple myeloma patients.
ENDEAVOR: Carfilzomib Doubles PFS in Relapsed Myeloma
Treatment with carfilzomib and dexamethasone doubled the PFS in relapsed multiple myeloma patients compared with treatment with bortezomib and dexamethasone.
Prior Knowledge of MGUS Linked to Improved Multiple Myeloma Survival
Multiple myeloma patients had better overall survival if they had prior knowledge of having monoclonal gammopathy of undetermined significance.
FDA Approves Panobinostat for Multiple Myeloma
The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.
FDA Approves Front-Line Lenalidomide for Multiple Myeloma
The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.